ALLERGY THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.85 GBX | 0.00% |
|
+7.55% | +14.00% |
| Apr. 03 | Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director | CI |
| Mar. 27 | EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line | AN |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 167.8 | 89.06 | 89.06 | 160.4 | 133.6 | 7.131 |
| Enterprise Value (EV) 1 | 155.4 | 64.06 | 64.28 | 131.3 | 123.6 | 28.27 |
| P/E ratio | -22.2 x | 26.9 x | 13.3 x | 58.2 x | -9.69 x | -0.16 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.46 x | 1.21 x | 1.14 x | 1.9 x | 1.84 x | 0.12 x |
| EV / Revenue | 2.27 x | 0.87 x | 0.82 x | 1.56 x | 1.7 x | 0.47 x |
| EV / EBITDA | -31.5 x | -64,060 x | 9.01 x | 21.5 x | -12.1 x | -0.85 x |
| EV / FCF | -49.4 x | -26.6 x | 11 x | 23.7 x | -10.8 x | -1.45 x |
| FCF Yield | -2.02% | -3.76% | 9.09% | 4.23% | -9.28% | -69% |
| Price to Book | 7.31 x | 2.37 x | 2.04 x | 3.31 x | 3.48 x | 3.45 x |
| Nbr of stocks (in thousands) | 594,118 | 636,169 | 636,169 | 641,773 | 643,999 | 679,105 |
| Reference price 2 | 0.2825 | 0.1400 | 0.1400 | 0.2500 | 0.2075 | 0.0105 |
| Announcement Date | 10/23/18 | 10/22/19 | 11/10/20 | 10/7/21 | 6/19/23 | 8/29/23 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 68.35 | 73.72 | 78.2 | 84.33 | 72.77 | 59.59 |
| EBITDA 1 | -4.94 | -0.001 | 7.137 | 6.113 | -10.24 | -33.08 |
| EBIT 1 | -6.704 | -1.836 | 4.992 | 3.926 | -12.37 | -35.19 |
| Operating Margin | -9.81% | -2.49% | 6.38% | 4.66% | -17% | -59.05% |
| Earnings before Tax (EBT) 1 | -6.896 | 4.293 | 8.071 | 3.657 | -12.66 | -41.77 |
| Net income 1 | -7.533 | 3.467 | 7.058 | 2.886 | -13.78 | -43.07 |
| Net margin | -11.02% | 4.7% | 9.03% | 3.42% | -18.93% | -72.28% |
| EPS 2 | -0.0127 | 0.005200 | 0.0105 | 0.004299 | -0.0214 | -0.0643 |
| Free Cash Flow 1 | -3.145 | -2.408 | 5.844 | 5.552 | -11.48 | -19.5 |
| FCF margin | -4.6% | -3.27% | 7.47% | 6.58% | -15.77% | -32.72% |
| FCF Conversion (EBITDA) | - | - | 81.88% | 90.83% | - | - |
| FCF Conversion (Net income) | - | - | 82.8% | 192.39% | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 10/23/18 | 10/22/19 | 11/10/20 | 10/7/21 | 6/19/23 | 8/29/23 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S1 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|
| Net sales 1 | 50.47 | - | 24.07 | 39.9 | 21.05 |
| EBITDA 1 | - | - | -17.9 | -5.837 | -26.07 |
| EBIT 1 | - | - | -19.66 | -7.957 | -28.17 |
| Operating Margin | - | - | -81.68% | -19.94% | -133.83% |
| Earnings before Tax (EBT) 1 | - | - | -19.92 | -8.2 | -41.63 |
| Net income 1 | - | 6.671 | -20.45 | -8.506 | -42.52 |
| Net margin | - | - | -84.94% | -21.32% | -201.99% |
| EPS 2 | 0.0227 | 0.009700 | -0.0311 | -0.0129 | -0.0632 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/4/20 | 3/3/22 | 9/29/22 | 6/19/23 | 9/27/23 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 21.1 |
| Net Cash position 1 | 12.5 | 25 | 24.8 | 29.1 | 9.99 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.6392 x |
| Free Cash Flow 1 | -3.15 | -2.41 | 5.84 | 5.55 | -11.5 | -19.5 |
| ROE (net income / shareholders' equity) | -28.4% | 11.4% | 17.4% | 6.25% | -31.7% | -216% |
| ROA (Net income/ Total Assets) | -7.74% | -1.92% | 4.03% | 2.82% | -9.57% | -31.5% |
| Assets 1 | 97.26 | -180.6 | 175 | 102.5 | 144 | 136.8 |
| Book Value Per Share 2 | 0.0400 | 0.0600 | 0.0700 | 0.0800 | 0.0600 | 0 |
| Cash Flow per Share 2 | 0.0300 | 0.0400 | 0.0600 | 0.0600 | 0.0300 | 0.0200 |
| Capex 1 | 2.01 | 2.81 | 2.26 | 2.56 | 3.06 | 4.67 |
| Capex / Sales | 2.93% | 3.81% | 2.89% | 3.04% | 4.2% | 7.84% |
| Announcement Date | 10/23/18 | 10/22/19 | 11/10/20 | 10/7/21 | 6/19/23 | 8/29/23 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +14.00% | 169M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- AGY Stock
- Financials Allergy Therapeutics plc
